An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms T-DM1 study
- Sponsors Chugai Pharmaceutical; Genentech; Roche
- 12 Oct 2017 Planned End Date changed from 28 Feb 2023 to 21 Sep 2022.
- 12 Oct 2017 Planned primary completion date changed from 30 Dec 2022 to 21 Sep 2022.
- 11 Sep 2017 Planned End Date changed from 28 Feb 2022 to 28 Feb 2023.